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ABSTRACT
In fec tions en coun tered in the sur gery of co lon and rec tum are se ri ous and of ten re quire a multi-dis ci plin ary
team. A typ i cal fea ture is the par tic i pa tion of mixed aer o bic + an aer o bic flora, poly-mi cro bial in num ber, and
syn er gis ti cally act ing in two phases: dur ing the first 4 – 5 days – de vel op ment of dif fuse peri to ni tis and
bacteraemia, gov erned by aer o bic or gan isms, and > 5 days: or ga ni za tion of in fec tion in ab scess with the main
par tic i pa tion of anaerobes. The com mon est patho gens among anaerobes are B. fragilis, pos sess ing cap su lar
polysaccharide, ad her ence po ten tial, piliation and toxin pro duc tion, fol low ing by B. fragilis group. Clostridia
may par tic i pate in the syn er gis tic poly-mi cro bial aer o bic-an aer o bic in fec tions, or to cause the typ i cal
clostridial myonecrosis. Ap pro pri ate spec i mens from the site of in fec tion in clude fluid/pus/as pi rate, col lected
by sy ringe and/or asep ti cally cut small tis sue piece. A set of two blood-cul tures should be ob tained. Suc cess ful
treat ment and man age ment of sec ond ary peri to ni tis and intra-ab dom i nal ab scesses de pends first on the ef fec -
tive sur gi cal in ter ven tion: to debride gross fibrinous de bris, drain age of pus and gross con tam i na tion from
the peritoneal cav ity; re sec tion or re pair of the pa thol ogy (per fo ra tion, tu mour etc). An ti bi otic ther apy con -
trib utes to lower both mor bid ity and mor tal ity. It should be large-spec trum, bac te ri cidal, pre scribed in suf fi -
cient dos age reg i men for enough time. Sec ond ary peri to ni tis, incl. the post-op er a tive in el derly and de bil i tated 
pa tients may cause par tic u lar chal lenge, es pe cially in pres ence of re sis tant or gan isms.
Keywords: intra-ab dom i nal, polymicrobial-, anaerobe- in fec tion, clin i cal pre sen ta tion, mi cro bi ol ogy
in ves ti ga tion, an ti bi otic ther apy
RISK OF INFECTION IN THE
SURGERY OF COLON AND RECTUM
In fec tions en coun tered in the sur gery of co lon and rec tum
are se ri ous and of ten re quire a multi-dis ci plin ary team (1).
They are com mu nity- or hos pi tal- ac quired; may be es tab -
lished be fore the op er a tion, or to de velop af ter the op er a tive 
pro ce dure (2-6). Me dian in crease in hos pi tal stay (LOS)
be cause of de vel op ment of sur gi cal site in fec tion (SSI) in
co lon sur gery is 6 days and the me dian in crease in cost/pa -
tient in USD is 2671 (7). Recto-sig moid co lon is known to
con tain the high est num ber of bac te ria in the body: 10 10 –
10 12 CFU/g stool. Wound even in elec tive in tes ti nal re sec -
tion, e.g. sig moid colectomy, as an ex am ple of clean-con -
tam i nated pro ce dures, would be con tam i nated at least by B. 
fragilis and E. coli and would ne ces si tate pro phy lac tic an ti -
bi otic to pre vent in fec tion, which arises in rates 4 – 10 %. In 
con tam i nated pro ce dures: e.g. elec tive with high in tes ti nal
spill age or emer gency laparatomy for stab/gun shot in jury,
rate of SSI is > 10 %. Dirty pro ce dures take place when ac -
tive in fec tion (pus) is al ready pres ent: acute intra-ab dom i -
nal peri to ni tis and ab scesses. Mod ern sur gery eval u ates
fur ther the risk for in fec tion. The sim pli fied NNIS (Na -
tional nosocomial in fec tion sys tem, USA) risk in dex is
char ac ter ized by points from 0 to 3: 1 point is given for con -
tam i nated or dirty op er a tion, an other point, if the pa tient has 
ASA score of 3, 4 or 5, and 1 more point, if the op er a tion
ex ceeds the 75th per cen tile of the stan dard de vel oped from
the NNIS database (8, 9). As a result, the colon surgery is
characterized by the highest risk category among all
surgical procedures (7):
T point (hrs) Risk Cat e gory 0 1 2     3
3.2 8.5 6.0   22.0
An other com pre hen sive sys tem, SIGN (Scot tish in ter col le -
giate guide line net work) (10), states the an ti bi otic pro phy -
laxis in colo-rec tal sur gery as highly rec om mended, be -
cause of pre vent ing both from in fec tion and mor tal ity with
Odds ra tio of 0.37 and 0.38; NNT (num ber needed to
threat) 5 and 17 respectiely, evidence level Ia.
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THE INFECTION IN COLO-RECTAL
SURGERY
In fec tion in colo-proc tol ogy most of ten is due to or gan isms
from the nor mal bowel flora (Ta ble 1).
A typ i cal fea ture is the par tic i pa tion of mixed aer o bic + an -
aer o bic flora, poly-mi cro bial in num ber, and syn er gis ti cally 
act ing in two phases: dur ing the first 4 – 5 days – de vel op -
ment of dif fuse peri to ni tis and bacteraemia, gov erned by
aer o bic or gan isms, and > 5 days: or ga ni za tion of in fec tion
in ab scess with the main par tic i pa tion of anaerobes (3,
13-16). Ab scess wall, den sity of bac te rial pop u la tions, acid
pH, low oxydo-re duc tion po ten tial pres ent real ob sta cles
for both an ti bi otic pen e tra tion and ac tiv ity (17).
As it can be seen from the Ta ble 1, the most fre quent par tic -
i pat ing aer obe or gan isms are E. coli and other
Enterobacteriaceae, which typ i cal fac tors of vir u lence are:
their endo tox ins (lipopolisaccharides), flagellae and pilli.
Enterococci and nonhaemolytic strep to cocci are not es pe -
cially vir u lent, but S. aureus and beta-haemolytic strep to -
cocci elab o rate va ri ety of tox ins and en zymes that de stroy
tis sues ag gres sively, and specific toxins may cause shock.
ANAEROBES: PATHOGENICITY,
RISK FACTORS, CLUES TO
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Different anaerobes Enterobacteriaceae, Streptococci,
S. aureus
Rectal surgery, cancer,















%:B. fragilis - 32, other Bacteroides 
- 44, Peptostreptococcus - 12,
Fusobacterium spp - 8
%: E. coli  64, Enterobacter/ Klebsiella
- 33, Proteus - 15,P. aeruginosa - 18,
Staphylococcus - 16, Enterococcus - 15





n: B. fragilis-47, BFGBS -14,
CSCP - 19, Prevotella - 9, 24
-Peptostreptococcus







B. fragilis - 34, BFGBS-44, CSCP - 
23, Prevotella - 19, Fusobacterium
-14, Peptostreptococcus-95
E. coli- 60, S. aureus -11,
Enterococcus - 19
Retroperitoneal abscess 










E. coli-19, S.aureus-34, Enterococcus
-9
Perirectal abscess




Diverticulitis B. fragilis-14, BFGBS-8,
Prevotella-10, Peptostreptococcus-6
E. coli-15, S.aureus-1, Enterococcus-3 Diverticulitis& n = 22 Brook I,
2002, JAC,
50; (13)
Leg end: BFGBS – Bacteroides fragilis group + Bacteroides spp; CSCP – Clostridium spp + C. perfringens




The com mon est patho gen amongst anaerobes is B. fragilis.
Its fac tors of vir u lence in clude (1,14): cap su lar
polysaccharide, ad her ence po ten tial, piliation and toxin
pro duc tion.  B. fragilis blood-cul ture iso lates are more
likely to carry an enterotoxin gene and to be more re sis tant
to an ti bi ot ics. Vir u lent patho gens of the B. fragilis group in -
clude also: B. thetaiotaomicron, B. distasonis, B. vulgatus,
B. ovatus, B. uniformis. The rate of iso la tion of B. fragilis is
~ 19 %, but it rises to 46 % in bacteraemia intra-ab dom i nal
iso lates. B. fragilis group ac counts for ~ 35 % of all
anaerobe iso lates. An aer o bic bacteraemia is not fre quent: 1
– 4 % of all bacteraemias; the most fre quent iso lates are B.
fragilis and Clostridium spp, al most al ways from bowel or -
i gin. It is es tab lished, that among sur gery pa tients ~ 25 % of 
bacteraemias em a nate from the large bowel, 5 % - from the
small bowel, 9 % - from ap pen dix, 9 % - fro exploratory
laparatomy (13-16).
Clostridia may par tic i pate in the syn er gis tic poly-mi cro bial
aer o bic-an aer o bic in fec tions, or to cause the typ i cal
clostridial myonecrosis, “gas gan grene”, where ~ 80 % of
iso lates are C. perfringens – the fast est grow ing anaerobe
(15,18,19). Collagenases and pro teas es pro duced by
clostridia de stroy the tis sues, whereas the al pha-toxin (letal
& ne crotic) con trib utes to the high mor tal ity rate ~ 60 %.
Sud den on set of pain at the site of the sur gi cal wound or
trauma, rap idly in creas ing in se ver ity and ex tend ing be -
yond the orig i nal bor ders is typ i cal. Skin is char ac ter ized by 
pale ap pear ance, then by oedematous/ hem or rhagic bullae
and foul-smell ing dis charge. Gram stains from dis charge
and tis sue sam ple show large Gram-pos i tive rods. When
the typ i cal ap pear ance and crepitations are in stalled, the pa -
tient may be near the death. Early debridement, hyperbaric
ox y gen a tion and Penicillin 24 million units are the present
treatment approach.
Risk fac tors for the de vel op ment of an aer o bic in fec tions
are: trauma, for eign body, ma lig nancy, sur gery, oe dema,
shock, co li tis, vas cu lar dis ease; they low the ox i da tion-re -
duc tion potential (7,20,21).
There are sev eral clues to clin i cal di ag no sis of an aer o bic in -
fec tion (20). The pres ence of pu trid smell and gas for ma tion in 
tis sues are caused by met a bolic end prod ucts: or ganic ac ids.
Other signs may be: in fec tion ad ja cent to a mucosal sur face,
clas sic pre sen ta tion (ne crotic gan gre nous tis sue, gas gan grene, 
ab scess); bacteraemia with out growth from aer o bic cul ture;
in fec tion re lated to tu mours, sep tic trombo-embolitis; in fec tion 
af ter an an ti bi otic course with ceftazidime, older quinolones,
aminoglycosides, co-trimoxazole. Anaerobes are fas tid i ous
and dif fi cult for iso la tion, they are of ten over looked. Iso la tion
of these or gan isms is im por tant to di rect an ti bi otic ther apy and
re quires spe cial/ap pro pri ate meth ods of col lec tion, trans por ta -
tion and cul ti va tion of spec i mens (1,14,17,20-22).
Ta ble 2 pres ents con tem po rary in for ma tion about sus cep ti -
bil ity pat terns of an aer o bic bac te ria (adapted from ref. 23
and 24).
As it con cerns Clostridium spp, Pen i cil lin G 24 mill U/24 h
is still con sid ered the treat ment of choice, al though cases of
pen i cil lin-re sis tance have been re ported in C. perfringens
(25). It is in ter est ing that new data showed in a mouse
model of C. perfringens in fec tion (gas gan grene) better out -
come af ter treat ment with clindamycin or metronidazole, or 
rifampicin, or chloramphenicol, or tet ra cy cline alone, as
well as of the com bi na tion clindamycin + pen i cil lin than
pen i cil lin G alone (25). In the same model the com bi na tion
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Bacteroides fragilis B. fragilis group Prevotella Fusobacterium Peptostreptococcus
Cefotaxime 30-50 > 50 5 5-15
Cefotetan 5-15 30-50 5-15
Cefoxitin 5 5-15 5 5 5
Ceftriaxone 16-30 > 50 5-15 5 5
Chloramphenicol 5 5 5 5 5
Clindamycin 5-15 16-30 5 5-30 10-15
Imipenem 5 5 5 5 5
Meropenem 5 5 5 5 5
Metronidazole 5 5 5 5 5
Penicillin G > 50 > 50 > 50 5-30 5
Augmentin 5 5-15 5 5-15 5
Piperacillin 5 5-15 5 5-15 5
Table 2. Antibiotic resistance in % in selected anaerobe bacteria. (Adapted from Ref. 23 and 24)
metronidazole + pen i cil lin showed an tag o nis tic ef fect. The
con clu sion drawn from these find ings is that it is better to
com bine clindamycin with pen i cil lin, but not




Pa tient with sus pected intra-ab dom i nal in fec tion com plains 
of ab dom i nal pain (but immuno-sup pressed or crit i cally ill
pa tients in ICU may not com plain (12). It is im por tant to
clar ify the on set, evo lu tion, lo cal isa tion and char ac ter of the 
pain. Pa tient will try to lie (even slight mo tion of the peri to -
neum causes dis com fort). Other symp toms as nau sea, vom -
it ing, di ar rhoea may be pres ent or not. Pro fuse di ar rhoea is
typ i cal for gas tro-en ter i tis, while the bloody – for ischemic
en ter i tis. Sur geon should ask where pa tient feels the point
of the most se vere pain. In spec tion, per cus sion, pal pa tion,
auscultation, im ag ing study (the best is com puted
tomography) will contribute to the clinical diagnosis.
The min i mum lab o ra tory tests in clude com plete blood
count, amylases, urinanalysis.
Crit i cally ill pa tients may need re sus ci ta tion (fluid re sus ci -




Clin i cal mi cro bi ol ogy in ves ti ga tion is a highly de sired pro -
ce dure when deal ing with in fec tion in colo-proc tol ogy
(7,12-19, 23, 25, 26):
1. Def i ni tion of SSI (CDC) ne ces si tates mi cro bi ol ogy
con fir ma tion of the in fec tion as one of the pos si ble
con sid er ations (su per fi cial – or gan/space in fec tion)
(27).
2. The need to know the par tic u lar patho gens in volved
and their an ti bi otic sus cep ti bil ity pat terns – in or der to
guide an ti bi otic ther apy
3. In fec tions in colo-proc tol ogy are typ i cally se vere and
even life-threat en ing: the haz ard in their ther apy should
be re placed by ev i dence-based clin i cal de ci sions
4. An ti bi otic re sis tance now a days is not rare, but typ i cal,
es pe cially in the hos pi tal set ting event, with dif fer ent
mech a nisms, epidemiologic spread and so cial
con se quences.
Ap pro pri ate spec i mens from the site of in fec tion in clude
fluid/pus/as pi rate, col lected by sy ringe and/or asep ti cally
cut small tis sue piece. These spec i mens should be ob tained
by the sur geon and dis posed onto the sur face of trans port
me dium (e.g. Stu art) in a tube. Then the spec i men should
be pushed to the bot tom of the tube (an aer o bic con di tions)
with a ster ile swab, by one punch through the me dium,
with out mak ing air bub bles. The tube should be sent to Mi -
cro bi ol ogy lab o ra tory, but this spec i men may wait for 24
hour at room tem per a ture un til be pro ceeded. An other pos -
si ble way is the pus/fluid, col lected in the sy ringe, with out
air, to be closed and im me di ately sent to the lab o ra tory
(when the lab o ra tory is in the same hos pi tal); this way re -
quire ur gent ac tiv i ties (re ceiv ing in 15’ – 30’) and is
more-de pend ent on the higher vol ume of spec i men for re -
cov er ing of anaerobes.
An other ap pro pri ate spec i men is blood-cul ture: two sets of
blood-cul tures –in aer o bic and an aer o bic bot tles each,
should be ob tained by the nurse at 20’ – 30’ apart.
Fas tid i ous anaerobes re quire much more time than usual to
re cover: an ti bi otic ther apy should not wait the
microbiologic re sult, but should be tai lored when the re sult
be comes avail able. Some times Gram stain (ur gent di ag no -





The first key to suc cess ful treat ment and man age ment of
sec ond ary peri to ni tis and intra-ab dom i nal ab scesses is the
ef fec tive sur gi cal in ter ven tion: to debride gross fibrinous
de bris (la vage), drain age of pus and gross con tam i na tion
from the peritoneal cav ity; re sec tion or re pair of the pa thol -
ogy (per fo ra tion, tu mour etc (21). Some pa tients re quire in -
ten sive care ther apy be cause of sep sis, hypovolemia and
hypoxia. What is the role of an ti bi otic treat ment? Among
all in fec tions of the co lon and rec tum and their con se -
quences, only non-com pli cated di ver tic u li tis (sigmoiditis
and recto-co li tis) could be treated by an ti bi ot ics with out
sur gery (17). In all other cases an ti bi ot ics play im por tant
role in pre ven tion and treat ment of in fec tion, and even in
pre ven tion of mor tal ity – they are of par a mount sig nif i -
cance for sav ing life, but there ac tiv ity can be ex erted in the
con di tion of good sur gi cal work (21). The sta tis ti cal data
shows that mor tal ity of intra-ab dom i nal in fec tion in 1900
has been ~ 90 %, in 1980 – 1990  ~ 25 % (20 – 50 %), now -
a days the prog no sis is im proved with the larger an ti bi otic
choice, asep sis, im proved di ag no sis and care for pa tients.
How ever, we should un der line the ad e quacy of “sur gi cal
source con trol” – ad e quacy of op er a tive pro ce dure for the
un der ly ing cause of peri to ni tis. Poorly cho sen, im prop erly
per formed op er a tion will cause an ti bi otic ef fect to fail
(CFU > 108 bac te ria/ml). Small abdominal abscess (d< 2
cm) sometimes may responds to antibiotic therapy alone,
but if the d > 4 cm, will not respond without drainage.
In brief, suc cess ful man age ment of se ri ous intra-ab dom i nal 
in fec tions will rely first on timely and ap pro pri ate sur gi cal
in ves ti ga tions that re solve the pri mary prob lem. Sup port ive 
care and an ti bi otic treat ment are nec es sary ad junct which
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1. An ti bi otic should be ap pro pri ately cho sen
They should be broad-spec trum to cover the most fre quent
aer o bic and an aer o bic patho gens. They should be quickly
act ing and bac te ri cidal. An ti bi ot ics should be ap pro pri ate
for the con crete type of in fec tion – e.g. com mu nity – or
hos pi tal- ac quired (Roehborn et al (28) have no ticed re -
cently higher rates of Enterococcus and Enterobacter in
nosocomial peri to ni tis). An ti bi ot ics should be the best for
the par tic u lar pa tient: e.g. not beta-lac tams if pen i cil lin al -
lergy, but e.g. aztreonam in stead; not aminoglycosides, if
re nal in suf fi ciency, but ciprofloxacin etc. An ti bi ot ics
should be given urgent in severe cases.
2. What dose, route, dos age in ter val?
The dose should be higher, to ob tain suf fi cient tis sue con -
cen tra tions for enough time at the site of in fec tion. The IV
route pro vides quick and high tis sue level. Dos age reg i men
should be op ti mal to main tain high an ti bi otic con cen tra -
tions (29). 
3. An ti bi otic re sis tance should be con sid ered (30)
The an ti bi otic cho sen should be ac tive on the in volved/sup -
posed patho gens. Lo cal Mi cro bi ol ogy lab o ra tory and na -
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Monotherapy Combined therapy Comments References
Augmentin
Beta-lactam + AG + nitro-imidazole 





Beta-lactam + AG + nitro-imidazole
Cephalosporin + nitro-imidazole




Cefoxitin or cefotetan or
Ampicillin/sulbactam or
Piperacillin/tazobactam
AG + clinda or metro or
IMP&ATM or FEP or CAZ or CIP
+ metro or clinda
Enterococcus - AMP or PIP; PEN allegy,
MRSA - vancomycin; Pseudomonas - AG +






-CAZ or FEP or PTZ or IMP
Triple combination that covers
Enterococcus, and Pseudomonas 




FOX, or CTA, or PTZ, or ETP, 
or IMP, or MER
AG or CFX or CEF3 or ATM or




PTZ or IMP or MER AG + clinda or metro




SAM or PTZ or FOX or CTA
or IMP or MER
clinda or metro + another
appropriate; sufficient dose
Documented R to traditional anti-anaerobes
Edmiston CE,
2002, CID; (16)
Beta-lactam/inhibitor (A) Clinda or metro + AG + PEN (B)
(B): immuno-suppression, late surgery,




PEN/inh; or CPZ/S; or ETP
AG + CAZ or FEP or CPZ/S or
PTZ or PEN/inh or AMP+ metro or
clinda
Post-operative peritonitis: penem; or FEP or




SAM or CTA or FOX or ETP
or IMP or MER or PTZ
AG + metro or clinda; ATM +
clinda; CFX or CIP+ metro; FEP or




PTZ or SAM or ETP&IMP or
MER - ICU







Leg end: PEN/inh – pen i cil lin/in hib i tor; PIP –piperacillin; PTZ-piperacillin/tzobactam; SAM, ampicillin-sulbactam; CPZ/S-
cefoperazone/sulbactam; AUG, augmentin; FOX, cefoxitin, CTA, cefotetan; CFX, cefuroxime; CAZ-ceftazidime; CTX –
cefotaxime; CRO – ceftriaxone; FEP, cefepime, ATM – aztreonam;ETP; ertapenem; IMP – imipenem; MER –meropenem; VAN –
vancomycin; CIP – ciprofloxacin; LVX – levofloxacin; CEF3 – cephalosporins 3
rd
 gen er a tion; AG – aminoglycosides
Table 3. Recommendations for antibiotic therapy of intra-abdominal infections
tional an ti bi otic sus cep ti bil ity data should be con sulted
(www.bam_bg.net). A com mon ap proach is the de-es ca la -
tion ther apy: first the em piric ther apy is broad-spec trum
and pow er ful to guar an tee broad-cov er age. Once the pa -
tient is go ing better and microbiologic re sult be comes
avail able, the ther apy is usu ally adapted by us ing more-nar -
row-spec trum an ti bi otic. If the pa tient con di tion is sta ble,
the an ti bi otic may be switched on (e.g. to apply PO
ciprofloxacin (same bioavailability as IV) (31).
An ti bi ot ics that do not se lect for an ti bi otic re sis tance should 
be pre ferred. In the up per case of hos pi tal-ac quired peri to -
ni tis (28) it was shown that cephalosporins us age had been
se lected for enterococci and Enterobacter. Cephalosporins
un con trolled us age se lects also P. aeruginosa be cause of
natural resistance.
The other sit u a tion – when the patho gens in cause are an ti -
bi otic-re sis tant, is much more dif fi cult to over come and
may be rea son the ther apy to fail. As a rule, nosocomial
bac te ria are more re sis tant. Im por tant re sis tant bac te ria of
sur gery in ter est are MRSA, which re quire ther apy with
vancomycin; ESBL-pro duc ing Enterobacteriaceae and
mul ti ple re sis tant P. aeruginosa, which re quire therapy
with carbapenems (32,33).
4. How long?
Con tem po rary guide lines sug gest that an ti bi otic pro phy -
laxis in sur gery should not ex ceed 24, max i mum 48 hours,
and ther apy in con tam i nated elec tive/ur gent pro ce dure – 5
days (34-40). How ever, ther apy of es tab lished se ri ous in -
fec tion: bac te rial sec ond ary peri to ni tis, ab dom i nal ab scess,
may re quire 3-4 weeks un til full regression of symptoms
(13,32,33). 
Ta ble 3 shows some ex am ples of con tem po rary an ti bi otic
ther apy for intra-ab dom i nal infections.
CONCLUSIONS
Suc cess ful man age ment of in fec tions in the sur gery of co -
lon and rec tum re quires knowl edge, sci en tific at ti tudes,
anal y sis, skills and fi nan cial re sources in both sur gery and
an ti bi otic ther apy. Multidisciplinary ap proach should be
used for better care of patients.
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